InnovAge Holding (INNV) Earnings Date & Reports

Key Takeaways

• InnovAge reported fiscal first quarter 2027 revenue of approximately $264.8 million, up roughly 12% from $236.1 million a year earlier and ahead of analyst expectations.
• Diluted earnings per share (EPS) came in at $0.14, comfortably above the consensus estimate of about $0.08.
• Net income attributable to InnovAge Holding Corp. rose to roughly $19.6 million, compared with $8.0 million in the prior-year quarter.
• Management reaffirmed its full fiscal 2027 revenue guidance range of $1.05 billion to $1.085 billion.
• Growth continues to be driven by higher participant census and member months across the company's PACE (Program of All-Inclusive Care for the Elderly) network.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available on Tickeron.
• Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

InnovAge Holding Corp. is a leading provider of care for high-cost, frail, predominantly dual-eligible seniors — those eligible for both Medicare and Medicaid — through the Program of All-Inclusive Care for the Elderly (PACE). The company's fiscal first quarter ended September 30, 2026, marks the opening chapter of what management calls "InnovAge 3.0," a shift from turnaround toward sustained growth after a fiscal 2026 in which adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) surged roughly 175%. With reimbursement-rate tailwinds expected to moderate, investors are watching closely whether census growth and center-level margins can keep profitability climbing on the strength of execution alone.

Reported Results

For its fiscal first quarter of 2027, InnovAge reported total revenue of approximately $264.8 million, up about 12% from $236.1 million in the same period a year ago and above the consensus estimate of roughly $257 million. Diluted EPS reached $0.14, beating the analyst consensus of about $0.08 by a wide margin and improving sharply from $0.06 a year earlier.

Net income attributable to InnovAge Holding Corp. climbed to roughly $19.6 million from $8.0 million in the prior-year quarter, reflecting both higher member months and improved operating leverage. Management also reaffirmed its full-year fiscal 2027 revenue outlook of $1.05 billion to $1.085 billion, signaling confidence in continued top-line expansion even as rate increases normalize.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors evaluating names like INNV alongside their broader watchlists.

Market Reaction and Investor Sentiment

Shares of InnovAge entered the report under pressure, having pulled back from their recent highs as investors weighed a more moderate reimbursement-rate environment and state-level rate negotiations in key markets such as California and Colorado. Against that backdrop, a top-and-bottom-line beat — and particularly the wide EPS outperformance — offered a reassuring signal on execution, and the stock was modestly higher in after-hours trading following the announcement. Sentiment remains centered on whether profitability gains can be sustained through organic census growth rather than relying on the rate tailwinds that supported fiscal 2026.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether InnovAge can convert its reaffirmed revenue guidance into continued margin expansion. Management has guided fiscal 2027 revenue to $1.05 billion to $1.085 billion, with census growth expected in the mid-single-digit to high-single-digit range as the company works toward roughly 8,625 to 8,850 participants by year-end.

Reimbursement dynamics remain a central variable. Medicare net rate increases are projected at only 1.5% to 2%, Medicaid increases are expected in the low single digits, and the transition to the V28 risk-adjustment model moves to a 50/50 blend in January 2027. Because California and Colorado together account for a large share of census, the pace of state rate finalization will be an important swing factor.

On the cost side, center-level contribution margin and external provider costs per participant will indicate whether operational discipline is holding as enrollment grows. Any update on de novo center losses, expansion opportunities, and technology investments will also help clarify the path toward the company's longer-term double-digit adjusted EBITDA margin target. As always, these observations are grounded in reported data and company guidance rather than price forecasts or investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations